Corcept Therapeutics (NASDAQ:CORT) Lowered to "Buy" at StockNews.com
Corcept Therapeutics (NASDAQ:CORT) Lowered to "Buy" at StockNews.com
Corcept Therapeutics (NASDAQ:CORT – Get Rating) was downgraded by investment analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a note issued to investors on Tuesday.
在周二发给投资者的一份报告中，斯托克新闻网的投资分析师将Corcept Treateutics(纳斯达克：CORT-GET评级)的评级从“强力买入”下调至“买入”。
Separately, HC Wainwright reduced their price objective on Corcept Therapeutics from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Friday, December 9th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Corcept Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $31.25.
另外，HC Wainwright将Corcept治疗公司的目标价从33.00美元下调至30.00美元，并在12月9日星期五的一份研究报告中对该股设定了“买入”评级。一名分析师对该股的评级为持有，四名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，Corcept Treeutics的共识评级为“中等买入”，平均目标价为31.25美元。
Corcept Therapeutics Stock Up 2.2 %
Corcept Treateutics股票上涨2.2%
Shares of CORT traded up $0.49 during midday trading on Tuesday, hitting $22.93. The company's stock had a trading volume of 575,478 shares, compared to its average volume of 575,558. Corcept Therapeutics has a one year low of $16.47 and a one year high of $30.14. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of 22.93 and a beta of 0.60. The company's fifty day simple moving average is $22.79 and its two-hundred day simple moving average is $25.48.
在周二午盘交易中，Cort的股价上涨了0.49美元，达到22.93美元。该公司股票的成交量为575,478股，而其平均成交量为575,558股。Corcept Treeutics的一年低点为16.47美元，一年高位为30.14美元。该股市值24.7亿美元，市盈率为22.93倍，贝塔系数为0.60。该公司的50日简单移动均线切入位为22.79美元，200日简单移动均线切入位为25.48美元。
Insider Activity
内幕活动
In other Corcept Therapeutics news, insider Gary Charles Robb sold 4,814 shares of Corcept Therapeutics stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $26.03, for a total transaction of $125,308.42. Following the transaction, the insider now directly owns 21,329 shares of the company's stock, valued at approximately $555,193.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Sean Maduck sold 25,000 shares of the company's stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $25.57, for a total value of $639,250.00. Following the sale, the insider now directly owns 56,462 shares of the company's stock, valued at approximately $1,443,733.34. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Gary Charles Robb sold 4,814 shares of the stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $26.03, for a total transaction of $125,308.42. Following the sale, the insider now owns 21,329 shares of the company's stock, valued at $555,193.87. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,439 shares of company stock valued at $1,040,958. Insiders own 18.60% of the company's stock.
在Corcept治疗公司的其他消息方面，内部人士Gary Charles Robb在11月22日星期二的一笔交易中出售了4,814股Corcept治疗公司的股票。该股以26.03美元的平均价格出售，总成交金额为125,308.42美元。交易完成后，这位内部人士现在直接持有该公司21,329股股票，价值约555,193.87美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过这个环节。在其他新闻方面，内部人士肖恩·马达克在11月10日星期四的一笔交易中出售了2.5万股该公司股票。这些股票的平均价格为25.57美元，总价值为639,250.00美元。出售后，这位内部人士现在直接持有该公司56,462股股票，价值约1,443,733.34美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在美国证券交易委员会网站。此外，内部人士加里·查尔斯·罗布在11月22日(星期二)的一笔交易中出售了4814股该股。该股以26.03美元的平均价格出售，总成交金额为125,308.42美元。出售后，这位内部人士现在持有该公司21,329股股票，价值555,193.87美元。关于这次销售的披露可以找到这里。在过去的90天里，内部人士卖出了40,439股公司股票，价值1,040,958美元。内部人士持有该公司18.60%的股份。
Institutional Trading of Corcept Therapeutics
Corcept治疗药物的制度性交易
Institutional investors have recently bought and sold shares of the company. Hennion & Walsh Asset Management Inc. bought a new stake in Corcept Therapeutics in the fourth quarter worth approximately $408,000. State of Alaska Department of Revenue lifted its position in shares of Corcept Therapeutics by 0.9% during the 4th quarter. State of Alaska Department of Revenue now owns 66,614 shares of the biotechnology company's stock valued at $1,352,000 after acquiring an additional 619 shares during the period. Bank of New York Mellon Corp boosted its stake in Corcept Therapeutics by 4.0% during the third quarter. Bank of New York Mellon Corp now owns 998,792 shares of the biotechnology company's stock worth $25,609,000 after acquiring an additional 38,453 shares in the last quarter. Teachers Retirement System of The State of Kentucky acquired a new stake in Corcept Therapeutics in the third quarter worth $804,000. Finally, Captrust Financial Advisors increased its stake in Corcept Therapeutics by 143.1% in the third quarter. Captrust Financial Advisors now owns 18,555 shares of the biotechnology company's stock valued at $476,000 after purchasing an additional 10,923 shares in the last quarter. Institutional investors own 80.08% of the company's stock.
机构投资者最近买卖了该公司的股票。Hennion&Walsh资产管理公司在第四季度购买了Corcept治疗公司价值约408,000美元的新股份。阿拉斯加州税务局在第四季度将其在Corcept Treeutics股票的头寸提高了0.9%。阿拉斯加州税务局目前持有这家生物技术公司66,614股股票，价值1,352,000美元，在此期间又购买了619股。纽约梅隆银行(Bank Of New York Mellon Corp)在第三季度将其在Corcept Treateutics的持股增加了4.0%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有这家生物技术公司998,792股股票，价值25,609,000美元，此前该公司在上个季度又收购了38,453股。肯塔基州教师退休系统在第三季度收购了Corcept Treeutics价值80.4万美元的新股份。最后，CapTrust Financial Advisors在第三季度将其在Corcept Treateutics的股份增加了143.1%。CapTrust Financial Advisors现在拥有18,555股这家生物技术公司的股票，价值476,000美元，上个季度又购买了10,923股。机构投资者持有该公司80.08%的股票。
About Corcept Therapeutics
关于Corcept Treateutics
(Get Rating)
(获取评级)
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Corcept Treateutics公司在美国发现、开发和销售治疗严重代谢、肿瘤和神经精神疾病的药物。该公司提供Korlym(米非司酮)片剂，作为每日一次的口服药物，用于治疗患有内源性库欣综合征的成年患者继发于高皮质醇血症的高血糖，这些患者患有2型糖尿病或葡萄糖耐受不良，且手术失败或不适合手术。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- United Airlines Soars Ahead of Earnings...Time to Deplane?
- Is Dividend King PPG Industries A Buy Before Earnings?
- Shocking New Documentary Exposes The Two Men Destroying America
- 3 Dividend Stocks For Passive Income
- UnitedHealth Group Stock: Is This The Bottom?
- 免费获取StockNews.com关于Corcept治疗(CORT)的研究报告
- 美国联合航空公司盈利前飙升...是时候下机了？
- 股息王PPG Industries是在盈利之前买入吗？
- 令人震惊的新纪录片揭露了两个摧毁美国的男人
- 3用于被动收益的股利股票
- UnitedHealth Group股票：这是底部吗？
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Corcept治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Corcept Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。